TY - JOUR
T1 - The immunostimulatory nature of mRNA lipid nanoparticles
AU - Sharma, Preeti
AU - Hoorn, Daniek
AU - Aitha, Anjaiah
AU - Breier, Dor
AU - Peer, Dan
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/2
Y1 - 2024/2
N2 - mRNA-Lipid nanoparticles (LNPs) are at the forefront of global medical research. With the development of mRNA-LNP vaccines to combat the COVID-19 pandemic, the clinical potential of this platform was unleashed. Upon administering 16 billion doses that protected billions of people, it became clear that a fraction of them witnessed mild and in some cases even severe adverse effects. Therefore, it is paramount to define the safety along with the therapeutic efficacy of the mRNA-LNP platform for the successful translation of new genetic medicines based on this technology. While mRNA was the effector molecule of this platform, the ionizable lipid component of the LNPs played an indispensable role in its success. However, both of these components possess the ability to induce undesired immunostimulation, which is an area that needs to be addressed systematically. The immune cell agitation caused by this platform is a two-edged sword as it may prove beneficial for vaccination but detrimental to other applications. Therefore, a key challenge in advancing the mRNA-LNP drug delivery platform from bench to bedside is understanding the immunostimulatory behavior of these components. Herein, we provide a detailed overview of the structural modifications and immunogenicity of synthetic mRNA. We discuss the effect of ionizable lipid structure on LNP functionality and offer a mechanistic overview of the ability of LNPs to elicit an immune response. Finally, we shed some light on the current status of this technology in clinical trials and discuss a few challenges to be addressed to advance the field.
AB - mRNA-Lipid nanoparticles (LNPs) are at the forefront of global medical research. With the development of mRNA-LNP vaccines to combat the COVID-19 pandemic, the clinical potential of this platform was unleashed. Upon administering 16 billion doses that protected billions of people, it became clear that a fraction of them witnessed mild and in some cases even severe adverse effects. Therefore, it is paramount to define the safety along with the therapeutic efficacy of the mRNA-LNP platform for the successful translation of new genetic medicines based on this technology. While mRNA was the effector molecule of this platform, the ionizable lipid component of the LNPs played an indispensable role in its success. However, both of these components possess the ability to induce undesired immunostimulation, which is an area that needs to be addressed systematically. The immune cell agitation caused by this platform is a two-edged sword as it may prove beneficial for vaccination but detrimental to other applications. Therefore, a key challenge in advancing the mRNA-LNP drug delivery platform from bench to bedside is understanding the immunostimulatory behavior of these components. Herein, we provide a detailed overview of the structural modifications and immunogenicity of synthetic mRNA. We discuss the effect of ionizable lipid structure on LNP functionality and offer a mechanistic overview of the ability of LNPs to elicit an immune response. Finally, we shed some light on the current status of this technology in clinical trials and discuss a few challenges to be addressed to advance the field.
KW - Adverse events
KW - Immunogenicity
KW - Ionizable lipids
KW - mRNA vaccines
KW - Structure–activity relationship
UR - http://www.scopus.com/inward/record.url?scp=85184285365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184285365&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2023.115175
DO - 10.1016/j.addr.2023.115175
M3 - Review article
C2 - 38218350
AN - SCOPUS:85184285365
SN - 0169-409X
VL - 205
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
M1 - 115175
ER -